University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Faculty Publications, Department of Psychology

Psychology, Department of

12-2013

Iptakalim attenuates self-administration and
acquired goal-tracking behavior controlled by
nicotine
S. Charntikov
University of Nebraska-Lincoln

N. Swalve
University of Nebraska-Lincoln

Steven T. Pittenger
University of Nebraska-Lincoln, s-spitten1@unl.edu

K. Fink
University of Nebraska-Lincoln

S. Schepers
University of Vermont-Burlington, scott.schepers@uvm.edu
See next page for additional authors

Follow this and additional works at: http://digitalcommons.unl.edu/psychfacpub
Part of the Behavioral Neurobiology Commons, Biological Psychology Commons, and the
Molecular and Cellular Neuroscience Commons
Charntikov, S.; Swalve, N.; Pittenger, Steven T.; Fink, K.; Schepers, S.; Hadlock, G. C.; Fleckenstein, A. E.; Hu, G.; Li, Ming; and
Bevins, Rick A., "Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine" (2013). Faculty
Publications, Department of Psychology. 694.
http://digitalcommons.unl.edu/psychfacpub/694

This Article is brought to you for free and open access by the Psychology, Department of at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Faculty Publications, Department of Psychology by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.

Authors

S. Charntikov, N. Swalve, Steven T. Pittenger, K. Fink, S. Schepers, G. C. Hadlock, A. E. Fleckenstein, G. Hu,
Ming Li, and Rick A. Bevins

This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/psychfacpub/694

NIH Public Access
Author Manuscript
Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

NIH-PA Author Manuscript

Published in final edited form as:
Neuropharmacology. 2013 December ; 0: . doi:10.1016/j.neuropharm.2013.07.019.

IPTAKALIM ATTENUATES SELF-ADMINISTRATION AND
ACQUIRED GOAL-TRACKING BEHAVIOR CONTROLLED BY
NICOTINE
S. Charntikova, N. Swalvea, S. Pittengera, K. Finka, S. Schepersa,1, G. C. Hadlockc, A. E.
Fleckensteinc, G. Hub, M. Lia, and R. A. Bevinsa
aDepartment of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE 68588,
USA
bJiangsu

Province Key Lab of Neurodegeneration, Department of Pharmacology, Nanjing Medical
University, Nanjing PR, China
cDepartment
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of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room
201, Salt Lake City, Utah 84112, USA

Abstract
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Iptakalim is an ATP-sensitive potassium channel opener, as well as an α4β2-containing nicotinic
acetylcholine receptor (nAChR) antagonist. Pretreatment with iptakalim diminishes nicotineinduced dopamine (DA) and glutamate release in the nucleus accumbens. This
neuropharmacological profile suggests that iptakalim may be useful for treatment of nicotine
dependence. Thus, we examined the effects of iptakalim in two preclinical models. First, the
impact of iptakalim on the interoceptive stimulus effect of nicotine was evaluated by training rats
in a discriminated goal-tracking task that included intermixed nicotine (0.4 mg/kg, SC) and saline
sessions. Sucrose was intermittently presented in a response-independent manner only on nicotine
sessions. On intervening test days, rats were pretreated with iptakalim (10, 30, 60 mg/kg, IP).
Results revealed that iptakalim attenuated nicotine-evoked responding controlled by the nicotine
stimulus in a dose-dependent manner. In a separate study, the impact of iptakalim on the
reinforcing effects of nicotine was investigated by training rats to lever-press to self-administer
nicotine (0.03 mg/kg/infusion). Results revealed that pretreatment with iptakalim (1, 3, 6 mg/kg,
IV) decreased nicotine intake (i.e., less active lever responding). Neither behavioral effect was due
to a non-specific motor effect of iptakalim, nor to an ability of iptakalim to inhibit DA transporter
(DAT) or serotonin transporter (SERT) function. Together, these finding support the notion that
iptakalim may be an effective pharmacotherapy for increasing smoking cessation and better
understanding its action could contribute medication development.
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Over 400,000 people in the United States die annually from tobacco-related diseases (CDC,
2008). It is estimated that $193 billion per year of expenditures are associated with health
care cost and loss of productivity related to the consumption of tobacco products (CDC,
2008). Even with a number of smoking cessation treatments available (e.g., Zyban®,
Chantix®), only about 20% of users remain abstinent for over a year (Schnoll and Lerman,
2006). Clearly there is still great need for new and effective treatments for nicotine
dependence.
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Iptakalim is an adenosine triphosphate-sensitive potassium channel opener that is approved
for use in treating hypertension in China (Wang et al, 2005a; Wang et al, 2005b). Along
with its action on potassium channels, iptakalim has several other neuropharmacological
effects that suggest that it could be used to treat nicotine dependence. For example,
iptakalim is an α4β2 nicotinic acetylcholine receptor antagonist (Hu et al, 2006). Nicotine
increases dopamine and glutamate release in the nucleus accumbens. Pretreatment with
iptakalim reduces this nicotine -induced intraccumbal dopamine and glutamate release (Hu
et al, 2006; Liu et al, 2006). Behaviorally, iptakalim under some conditions can decreases
nicotine-induced hyperactivity (Hu et al, 2006; Liu et al, 2006; Volf et al, 2012). Given
these findings, the first goal of the current research was to examine the effect of iptakalim on
nicotine in two separate animal models: the discriminated goal-tracking task that assesses
the interoceptive stimulus effects of nicotine and the intravenous (IV) drug selfadministration task that assess the positive reinforcing effects of nicotine.
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The interoceptive stimulus effects of nicotine and the associated learning processes are
thought to be important to chronic tobacco use and nicotine dependence (Bevins and
Palmatier, 2004). Indeed, the pharmacological effects of nicotine that generate a perceptible
internal stimulus (cf. drug intoxication) can come to control reinforced behaviors in rodents
and primates—including humans (for reviews see Smith and Stolerman, 2009; Wooters et
al, 2009). In the present study, we used the drug discriminated goal-tracking (DGT) task
with rats to investigate the effects of iptakalim on the interoceptive stimulus effects of
nicotine (Besheer et al, 2004; Bevins et al, 2012). In this task, rats receive intermixed
sessions of nicotine and saline. In nicotine sessions, sucrose is available intermittently
regardless of behavior; during saline sessions, sucrose is unavailable. After a period of
training, nicotine comes to evoke a robust anticipatory food-seeking response, or what is
often referred to as goal-tracking. In the DGT, this food-seeking response translates into an
increase in head-entries into a dipper receptacle where sucrose has occurred in the past
(Farwell and Ayres, 1979). This discriminated goal-tracking response is mediated by
centrally located nicotinic acetylcholine receptors (Besheer et al, 2004; Struthers et al,
2009). The α4β2-containing receptors seem to be of particular importance. For example, the
α4β2 partial receptor agonist varenicline and the α4β2 agonists ABT-418 fully substitute for
the nicotine stimulus in the DGT task (Reichel et al, 2010). Further, the α4β2 antagonist
dihydro-β-erythroidine blocks conditioned responding evoked by the nicotine stimulus
(Struthers et al, 2009).
Another factor contributing to chronic tobacco use is the reinforcing effect of nicotine
(Henningfield and Goldberg, 1983; Le Foll and Goldberg, 2009; Stolerman and Shoaib,
1991). Intravenous nicotine self-administration in rats has been commonly used to assess the
reinforcing effects of nicotine. In this task, rats have a catheter implanted into the jugular
vein. Rats are then given an opportunity to make one of two responses (e.g., press on the
right or left lever). Responding as prescribed by the experimenter on one of the two levers
will produce an infusion of nicotine; responding on the other inactive lever has no
programmed consequence. Nicotine self-administration, as indicated by greater responding
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on the drug lever, has been demonstrated in many laboratories (Caggiula et al, 2002;
Corrigall and Coen, 1989; DeNoble and Mele, 2006; Donny et al, 1995; Feltenstein et al,
2012; Neugebauer et al, 2006). The α4β2 antagonist DHβE attenuates nicotine selfadministration (Grottick et al, 2000; Tobey et al, 2012; Watkins et al, 1999).
We found that iptakalim attenuated responding in the DGT task and decreased the intake of
nicotine in the self-administration task. Monoamine transporter inhibition can likewise
diminish these behaviors. For example, pretreatment with the selective serotonin reuptake
inhibitor citalopram blocks nicotine-evoked responding in the DGT task (Dion et al., 2012).
Further, the dopamine reuptake inhibitor bupropion substitutes for the nicotine stimulus
(Wilkinson et al., 2010). Given these findings, a second goal of the present research was to
examine the effects of iptakalim on DAT and SERT to determine if these transporters
contribute to iptakalim’s mechanism of action.

MATERIALS
Animals

NIH-PA Author Manuscript

Thirty male Sprague-Dawley rats weighing 275–299 grams upon arrival from Harlan
(Indianapolis, IN, USA) were housed individually in clear polycarbonate cages
(48.3×26.7×20.3 cm) lined with wood shavings. The temperature- and humidity-controlled
colony was on a 12-h light/dark schedule (lights on at 0600); experiments were conducted
during the light cycle. Water was freely available in the home cage. Rats’ weight in the DGT
task was maintained at 85% of their free-feeding body weight. For rats in the selfadministration study, chow was available ad libitum for the day before surgery and the 6
days following surgery. Otherwise, rats were maintained at 90% of their free-feeding body
weight. Four weeks into the self-administration study, the target weight was increased by 2 g
to adjust for average growth pattern provided by the supplier. Experimental protocols were
approved by the University of Nebraska-Lincoln Institutional Animal Care and Use
Committee.
Apparatus
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The conditioning chambers (ENV-008CT; Med Associates, Inc.; St. Albans, VT, USA)
measuring 30.5×24.1×21.0 cm (l×w×h), were enclosed in a sound- and light-attenuating
cubicle equipped with an exhaust fan. Each chamber had aluminum sidewalls, metal rod
floors with polycarbonate front, back, and ceiling. A recessed receptacle (5.2×5.2×3.8 cm;
l×w×d) was centered on one sidewall. A dipper arm, when raised, provided access to 0.1 ml
of 26% (w/v) sucrose solution in the receptacle. Access to the dipper was monitored by an
infrared beam mounted 1.2 cm into the receptacle and 3 cm above the floor. A second
infrared beam that monitored chamber activity was located 4 cm above the floor and 14.5
cm from the side wall containing the receptacle. Two retractable levers (147 nN required for
micro-switch closure) were mounted on each side of the receptacle. A white cue-light (2.54
cm diameter; 28V, 100 mA) was mounted 7 cm above each lever. A house light (two white
28V, 100 mA lamps) was located 10 cm above the conditioning chamber. The infusion
pump (PMH-100VS; Med Associates; St. Albans, VT, USA) for each chamber was located
outside the sound-attenuating cubicle. A 5-ml syringe mounted on the infusion pump was
connected with Tygon® tubing (AAQ04103; VWR; West Chester, PA, USA). The tubing
was attached to a swivel coupled with a spring leash (C313C; Plastics One; Roanoke, VA,
USA) which were suspended over the ceiling of the chamber on a balanced metal arm. Med
Associates interface and software (Med-PC for Windows, version IV) were used to collect
data and present programmed events
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Drugs—(−)-Nicotine hydrogen tartrate (Sigma; St. Louis, MO, USA) and iptakalim
hydrochloride (99.9%; synthesized and provided by the Institute of Pharmacology and
Toxicology, Academy of Military Medical Sciences of China) were dissolved in 0.9%
saline. The pH of the nicotine solution was adjusted to 7.0±0.2 with a dilute NaOH solution.
Nicotine doses (reported as base), iptakalim doses (reported as salt), route of injection, and
injection-to-placement intervals (i.e., time between the injection and the onset of behavioral
assessment) were selected based on previous research (Charntikov et al, 2012; Murray and
Bevins, 2007a, b; Sun et al, 2010). In the DGT study, nicotine was administered
subcutaneously (SC) and iptakalim was administered intraperitoneally (IP) at a volume of 1
ml/kg. In the self-administration study, nicotine was infused intravenously (IV) 35.74 μl per
infusion across 1 sec; iptakalim was administered IV at 1 ml/kg (see later for more detail).

METHODS
Discriminated goal-tracking task

NIH-PA Author Manuscript
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Rats in this study (n=10) were trained on our standard DGT protocol (as previously
described in Bevins et al, 2012; Wilkinson et al, 2010). Before this study, these rats served
in a separate experiment investigating how drug combinations, some of which bind to
nAChRs (e.g., sazetidine A, nornicotine, bupropion), affected responding. This use of
trained animals in the drug discrimination field, and in our lab specifically, is common given
that performance is reliable and repeatable across time (Polewan et al, 2013; Smith et al,
2009; Struthers et al, 2009; Wooters et al, 2009). For the present study, all rats were tested
on all doses of iptakalim using a repeated 5-day testing cycle. The first 4 days of this
standardized testing protocol were training sessions to insure the nicotine/saline
discrimination was maintained. For each daily training session, rats were injected SC with
either nicotine (0.4 mg/kg) or saline 5 min before placement into the chamber for a 20-min
session. There were 2 nicotine and 2 sucrose sessions intermixed per 4-day training cycle.
Access to sucrose was initiated between 124 to 152 s from the start of the nicotine session.
There were 36 separate 4-sec deliveries of sucrose per nicotine session. Time between
sucrose deliveries ranged from 4 to 80 s (mean = 25 s). Sucrose was unavailable during the
saline sessions. On day 5 of the test cycle, rats were injected with a randomly assigned dose
of iptakalim (0, 10, 30, or 60 mg/kg; IP) 10 min before the start of a 4-min test session;
nicotine was administered 5 min before the test. During test sessions, head entries into the
dipper receptacle and general chamber activity were recorded, but sucrose was not available.
Once all doses of iptakalim in combination with nicotine were tested, we noted that the
combination with 60 mg/kg iptakalim decreased chamber activity. To determine if iptakalim
impaired spontaneous locomotion in a manner that could account for the decrease in goaltracking behavior evoked by the nicotine stimulus, we then tested all doses of iptakalim
alone (no nicotine). These tests proceeded similar to those previously described except
saline replaced nicotine as the solution injected 5 min before the 4-min test session. For all
DGT sessions, the house light remained off and both levers were retracted.
IV nicotine self-administration task
Preliminary training—Before the start of this study, a separate set of rats (n=20) were
handled for a minimum of 2 min per each of three consecutive days. Rats were then trained
to lever press. The start of each lever-press session was signaled by illumination of the
house light and insertion of a randomly selected lever (right or left). A lever press or a lapse
of 15 sec resulted in 4-sec access to sucrose, retraction of the lever, and commencement of a
timeout that lasted on average 60 s (range=30 to 89 s). Following the timeout, a randomly
selected lever was again inserted into the chamber with the condition that the same lever
could not be presented more than 2 times in a row. This protocol was repeated for 60
sucrose deliveries. Daily sessions ranged from 65–80 min, depending on individual
Neuropharmacology. Author manuscript; available in PMC 2014 December 01.
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insertions for two consecutive days (i.e., 3 to 5 training sessions).
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Catheter surgery—Following at least 24 h after preliminary training, rats were
anesthetized with 1 ml/kg ketamine (100 mg/ml) and xylazine (20 mg/ml) mixture (2:1 ratio;
administered intramuscularly; Sigma; St. Louis, MO, USA). Polyurethane catheter
(RJVR-23; Strategic Applications Inc.; Lake Villa, IL, USA) with rounded tip and double
suture beads (one secured internally and other externally) was implanted into the right
external jugular vein. The other end of the catheter was subcutaneously placed around the
shoulder and exited below the scapula via subcutaneously implanted polycarbonate backmount access port (313-000BM; Plastics One Inc.; Roanoke, VA, USA). Immediately
following surgery, catheters were flushed with 0.2 ml of streptokinase (2 mg/ml; Sigma; St.
Louis, MO, USA) diluted in sterile heparinized saline (30 U/ml; Midwest Veterinary
Supply; Lincoln, NE, USA). Atipamezole hydrochloride (0.5 mg/kg; IM; Sigma; St. Louis,
MO, USA) diluted in saline was used to terminate anesthesia (Wee et al, 2006). To manage
post-surgical pain, buprenorphine hydrochloride (0.1 mg/kg; SC) was administered
immediately after the surgery and daily for the next two recovery days. Starting from the
day after surgery, catheters were flushed daily with heparinized saline (30 U/ml). Catheter
patency was assessed when patency loss was suspected or upon completion of the selfadministration study using an infusion of 0.05 ml xylazine (20 mg/ml; IV). This xylazine
concentration produces motor ataxia within 5 sec (cf. Bevins, 2005; Reichel et al, 2008).
Only the 13 rats with patent catheters were included in the analyses.
Continued preliminary training—Following 7 days of recovery from surgery in the
home cage, rats were trained for 3 consecutive daily sessions to lever press for liquid
sucrose on a variable ratio (VR3) schedule of reinforcement (i.e., on average every third
response was followed by access to sucrose; range=1 to 6 presses). This training was similar
to the pre-surgery training except lever pressing was now required to access sucrose. Across
the 3 daily sessions, all rats earned at least 80% of the 60 available sucrose deliveries and
were thus moved to the self-administration phase (Nb. this protocol insures a high baseline
level of lever pressing with both levers having a similar reinforcement history).

NIH-PA Author Manuscript

Nicotine self-administration—Before the start of each 60-min self-administration
session, catheters were flushed with 0.2 ml of heparinized saline. The start of each session
was signaled by turning the house light off, priming the catheter with nicotine (ca. 31 μl or
90% of internal catheter volume), and insertion of both levers. Which lever served as the
active lever was balanced across the rats. The active lever was reinforced on aVR3 schedule
of reinforcement. A VR schedule was used because in preliminary studies in our laboratory,
this reinforcement schedule produced more reliable self-administration and lever
discrimination than other schedules (e.g., fixed ratio [FR] 1 or FR5). Further, VR schedules
typically control high and steady rates of behavior which may provide enhanced sensitivity
to experimental manipulations (Williams, 1988). Upon completion of the VR3, there was a
1-sec infusion of nicotine (0.01 mg/kg/infusion), retraction of both levers, and illumination
of the house light for a 20-sec timeout. Following the timeout, the house light was turned off
and levers were inserted back into the chamber. Inactive lever responding was recorded but
there was no programmed consequence. Immediately after each self-administration session,
catheters were flushed with the antibiotic cefazolin (10 mg) diluted in 0.2 ml of heparinized
saline (30 U/ml). After rats had reached a criterion of 80% discrimination between the active
and inactive lever, iptakalim testing commenced.
Iptakalim dose response—Iptakalim (0, 1, 3, or 6 mg/kg) was administered IV 5 min
before the start of the self-administration session. The IV route was adopted because of
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limited drug availability at the time of the experiment. The 10 fold decrease in doses for
iptakalim for IV administration was adapted from Bardo et al (1999). All doses were tested
in a randomly selected order for each rat. Following each test day there were at least 2
iptakalim-free self-administration sessions. At least 80% responding had to be on the active
lever before being tested with the next randomly selected iptakalim dose.
[3H]dopamine and [3H]serotonin uptake
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Inhibition of [3H]dopamine and [3H]serotonin uptake by iptakalim was determined using a
rat striatal (dopamine) or hippocampal (serotonin) synaptosomal preparation previously
described (Hadlock et al, 2011). Briefly, synaptosomes were prepared by homogenizing
freshly dissected striatal or hippocampal tissue in ice-cold 0.32 M sucrose pH 7.4, and
centrifuged (800 × g, 12 min; 4°C). The supernatants were centrifuged (22,000 × g, 15 min;
4°C) and the resulting pellets were re-suspended in ice-cold assay buffer (in mM: 126 NaCl,
4.8 KCl, 1.3 CaCl2, 16 sodium phosphate, 1.4 MgSO4, 11 glucose and 1 ascobic acid; pH
7.4) and 1 μM pargyline. Iptakalim (1 nM–1 mM) was present in the assay tubes. Samples
were incubated for 10 min at 37°C and the assays initiated by the addition of [3H]dopamine
or [3H]serotonin (0.5 nM or 5 nM final concentration, respectively). Following incubation
for 3 min, samples were placed on ice to stop the reaction and were filtered through GF/B
filter paper (Whatman; Florham Park, NJ, USA) soaked previously in 0.05%
polyethylenimine. The filter paper was rapidly washed three times with 3 ml of ice-cold 0.32
M sucrose buffer using a filtering manifold (Brandel; Gaithersburg, MD, USA). For
[3H]dopamine uptake, nonspecific values were determined in the presence of 50 μM
cocaine. For [3H]serotonin uptake, nonspecific values were determined in the presence of 10
μM fluoxetine. Radioactivity trapped in the filter paper was counted using a liquid
scintillation counter.

STATISTICAL ANALYSES
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An omnibus analysis of variance (ANOVA) preceded all planned comparisons. Higher-order
interactions were further analyzed by two-way ANOVAs or ANCOVA and followed, if
necessary, by Tukey’s HSD post-hoc tests. Statistical significance was set at p<0.05. To
examine the effect of iptakalim on dipper entry rates and chamber activity, a separate oneway ANOVA with iptakalim dose as the within-subjects factor was performed. To fully
assess the potential locomotor effects of iptakalim on nicotine-associated activity, a separate
LSD comparisons to a saline control (0 mg/kg iptakalim + saline; dashed line on Figure 1B)
were conducted. The magnitude and persistence of nicotine self-administration behavior was
assessed using a 2×6 (Lever × Session) repeated measures ANOVA. The effect of iptakalim
on nicotine self-administration behavior was analyzed using a 2×4 (Lever × Dose) ANOVA.
To examine the effect of iptakalim on general chamber activity during nicotine selfadministration, a one way ANOVA with iptakalim doses as independent and activity as
dependent variables was performed. To examine the effect of iptakalim and cocaine on
striatal and hippocampal synaptosomal [3H]dopamine and [3H]serotonin uptake,
respectively, IC50 values were assessed using a least squares, non-linear regression fit with a
minimum of seven data points (determined in triplicate) per curve.

RESULTS
Discriminated goal-tracking task
Figure 1 shows the impact of iptakalim in the DGT task. Iptakalim attenuated nicotineevoked conditioned responding [main effect of Dose; F(3,27)=20.87, p<0.001; Figure 1A].
Dipper entries following pretreatment with 30 and 60 mg/kg iptakalim were significantly
lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests). Iptakalim
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also attenuated chamber activity in these nicotine test sessions [main effect of Dose;
F(3,27)=12.53, p<0.01; Figure 1B]. Pretreatment with 30 and 60 mg/kg of iptakalim
decreased activity relative to saline or 10 mg/kg iptakalim (Tukey HSD tests). When this
chamber activity was compared to a saline control value (i.e., both injections were saline;
dashed line on Figure 1B) only pretreatment with 60 mg/kg of iptakalim significantly
reduced activity (LSD comparisons). Notably, in these brief 4-min test sessions, nicotine did
not have a locomotor stimulant effect; no difference in chamber beam breaks between the
nicotine and the saline alone condition.
Because iptakalim attenuated activity of nicotine-treated rats, an additional mixed general
linear model ANCOVA was performed with dipper entries as a dependent measure,
iptakalim dose as the within-subjects variable, and chamber beam breaks as the covariate.
This ANCOVA revealed that blockade of nicotine-evoked dipper entries [main effect of
Dose; F(3,23)=19.73, p<0.001] cannot be explained by the variance in activity during the
test session [no main effect of Activity and no Activity by Dose interaction]. Furthermore,
iptakalim did not affect dipper entries or chamber activity (n.s.) in saline-treated rats (Figure
1C and 1D). Combined, these findings suggest that antagonism of the stimulus effects of
nicotine by iptakalim cannot be attributed to a non-specific motor effect of iptakalim.
IV nicotine self-administration task
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Figure 2 shows the impact of iptakalim in a second preclinical model of nicotine abuse
liability—nicotine self-administration. During the first 6 days of self-administration,
responding on the active lever was significantly higher than on the inactive lever [main
effect of Lever; F(1,216)=265.15, p<0.001; Figure 2A]. This difference was evident from
day 1 on [Lever × Session interaction; F(5,216)=3.00, p<0.05; Tukey HSD tests].
Pretreatment with iptakalim significantly attenuated responding on the active lever without
affecting responding on the inactive lever [main effect of Lever; F(1,13)=120.10, p<0.001;
Lever × Dose interaction; F(3,39)=12.61, p<0.001; Tukey HSD tests; Figure 2B].
Specifically, all iptakalim doses significantly attenuated active lever responding in
comparison to saline [separate one-way ANOVA; main effect of Dose; F(3,39)=15.59,
p<0.001; Tukey HSD tests; Figure 2B]. Iptakalim also decreased chamber activity [main
effect of Dose; F(3,39)=5.96, p<0.01; Figure 2C]. A follow-up mixed general linear model
ANCOVA on the active lever responding with the total chamber beam breaks as a covariate
revealed that the attenuation of nicotine intake by iptakalim [main effect of Dose;
F(3,35)=16.07, p<0.001] cannot be explained by alterations in activity [no main effect of
Activity; F(1,35)=0.34, p=0.55; and no Activity by Dose interaction; F(3,35)=1.61, p=0.20].
[3H]dopamine and [3H]serotonin uptake
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Ligands that act, in part, by inhibiting monoamine transporters interfere with nicotineevoked goal-tracking and nicotine self-administration (Di Chiara, 2000; Dion et al, 2012;
Rauhut et al, 2003; Wilkinson et al, 2010). Thus, the impact of iptakalim per se on
dopamine and serotonin transporter function was evaluated. Findings from the present study
revealed that iptakalim was without effect, at concentrations ranging from 1 nM – 0.1 mM,
on either [3H]dopamine or [3H]serotonin uptake, as assessed in striatal and hippocampal
synaptosomes, respectively (see Figure 3). As in internal control to verify the integrity of the
assay, IC50 values for cocaine (present in the assay tubes at concentrations of 1 nM–0.1
mM) were also evaluated. Consistent with our previous report (Hadlock et al, 2011), cocaine
inhibited [3H]dopamine and [3H]serotonin uptake with IC50 values of 1212 nM and 922 nM,
respectively.
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The known neurobiological and behavioral effects of iptakalim suggest that it may be an
effective pharmacotherapy to aid in smoking cessation. A goal of the present research was to
test this notion by examining the effect of iptakalim on the stimulus and on the reinforcing
effects of nicotine in two preclinical rodent models: a) drug discriminated goal-tracking and
b) IV nicotine self-administration. We found that iptakalim, in a dose-dependent manner,
attenuated conditioned responding controlled by the nicotine stimulus and attenuated
nicotine intake by selectively decreasing active lever pressing.
Previous research from our laboratory has implicated the DAT and SERT in the stimulus
effects of nicotine using the DGT task. For example, bupropion, a dopamine transporter
inhibitor, fully substitutes for the stimulus effects of nicotine. Conversely, the SERT
inhibitor, citalopram, blocks the conditioned response controlled by the nicotine stimulus
(Dion et al, 2012). However, since iptakalim did not appreciably inhibit SERT or DAT
function, another mechanism(s) likely underlies its effects on the stimulus and reinforcing
effects of nicotine.
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Very little data are available concerning the affinity of iptakalim on various receptor
subtypes. In fact, one novel finding from the current study is that iptakalim does not inhibit
dopamine or serotonin transporter function. Instead, antagonism of α4β2 receptors likely
contributes to the efficacy of iptakalim demonstrated in Figures 1 and 2. In fact, heteromeric
nAChRs are established contributors to the stimulus effects of nicotine. Evidence of the
importance of these receptors includes the finding that agonists like ABT-418, ABT-594,
A85380, TC2559, epibatidine, nornicotine, and 5-IA that bind to α4β2–containing nAChRs
fully substitute for the nicotine stimulus (Brioni et al, 1995; Cohen et al, 2003; Reichel et al,
2010; Smith et al, 2007). Partial α4β2 agonists like cytisine and varenicline substitute for
nicotine stimulus either partially or fully depending on the study (Chandler and Stolerman,
1997; Jutkiewicz et al, 2011; LeSage et al, 2009; Reichel et al, 2010; Smith et al, 2007).
The α4β2 antagonist DHβE fully blocks the stimulus effects of nicotine (Struthers et al,
2009; Zaniewska et al, 2006). In addition, α4β2-containing nAChRs appear necessary for
nicotine self-administration (Picciotto et al, 1998). Further, selective activation of α4β2containing nAChRs is sufficient to establish nicotine place preference demonstrating critical
involvement of these receptors in the reinforcing/rewarding effects of nicotine (Tapper et al,
2004). Finally, iptakalim inhibits the function of dopaminergic neurons dissociated from
substantia nigra by non-competitively antagonizing α4-containing (α4β2 and α4β4) nAChRs
localized on these neurons (Hu et al, 2006).
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The brief overview in the previous paragraph suggests a likely role for α4-containing
nAChRs in effects of iptakalim in the present experiments. It is worth noting, however, that
iptakalim’s actions on KATP channels may also contribute to blockade of the reinforcing and
stimulus effect of nicotine. For example, the KATP channels is located in brain areas
implicated in both reward and learning processes – ventral tegmental area, substantia nigra,
the prefrontal cortex, and hippocampus (Ross et al, 2006). KATP channels located in these
areas play an important role in regulating glutamatergic, dopaminergic, and GABAergic
neurotransmission (Ross et al, 2006), all of which play a role in the behavioral and neural
effects of nicotine (Dwoskin et al, 2009; Wooters et al, 2009).
In the discriminated goal-tracking and the self-administration task, iptakalim reduced
chamber activity. At first, these finding might suggests that its antagonism of the stimulus
and reinforcing effects of nicotine are the by-product of non-specific motor effects by
iptakalim. There are several finding that make this account less tenable. First, an effect on
activity was not observed after iptakalim per se, but only when iptakalim was administered
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along with nicotine at the highest test dose (60 mg/kg) in the DGT task. In fact, the stimulus
effects of nicotine in the DGT task were also blocked by iptakalim at 30 mg/kg; a dose that
did not significantly alter activity. Second, the ANCOVAs that used chamber activity as a
covariate revealed that the reduction in locomotion did not significantly contribute to the
decrease in nicotine-evoked goal-tracking or the reduction in nicotine-maintained active
lever pressing. Finally, in other published experiments, iptakalim increases locomotor
activity when administered alone (10 mg/kg IP; Schmidt et al, 2012) or decreases
locomotion when administered with stimulants like nicotine or amphetamine (Sun et al,
2010; Volf et al, 2012). We did not observe this increase in activity when iptakalim was
given alone (recall Figure 1D). Perhaps the brief 4-min test sessions used here were not
sufficiently long to detect this enhanced activity (cf. 60 min in Schmidt et al, 2012). Of
course, there are many other potential methodological differences that could account for this
discrepancy (e.g., size of apparatus, how activity was indexed, experimental history, rat
strain, etc.). Regardless, iptakalim attenuated the stimulus and positive reinforcing effects of
nicotine with motor impairment seeming an unlikely account of this blockade.
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Nicotine is the primary addictive component of tobacco and purportedly its reinforcing
effects are important to the addiction process (Balfour, 2002; Pomerleau and Pomerleau,
1992). However, recent research has highlighted the relative import of its reward or
incentive-enhancing effects. For example, low levels of responding can be maintained in rats
by a change in visual stimuli as the consequence for completing a schedule of reinforcement.
Responding maintained by this visual stimulus is increased significantly when nicotine is
administered by the experimenter before the session or by the rat during the session
(Caggiula et al, 2001; Chaudhri et al, 2006, 2007; Palmatier et al, 2007). In our selfadministration protocol, we used cued timeouts (see Methods) following each nicotine
infusion. One might justifiably speculate that the nicotine self-administration seen in the
present study reflects the primary reinforcing effects of nicotine plus its reward-enhancing
effects on the visual stimulus that signaled the infusion and subsequent timeout. If so, then
the decrease in nicotine intake seen with iptakalim may reflect blockade of either of these
effects of nicotine, or both.

NIH-PA Author Manuscript

Although we did not design the present experiments to distinguish between the import of the
primary reinforcing effects of nicotine or its reward-enhancing effects on the visual
stimulus, the potential implication of the research in this report remains the same. The
demonstrated behavioral effects here on the nicotine-evoked goal-tracking and nicotine
intake suggest that it should be further investigated as a pharmacotherapy for smoking
cessation. The known neural effects of iptakalim on nicotine-induced dopamine release and
binding to α4β2-containing nAChRs are consistent with this suggestion. Given the limited
research on iptakalim within the context of nicotine dependence and smoking cessation,
much more research is needed. For example, will iptakalim blunt reinstatement (relapse) of
self-administration behavior triggered by an environmental stressor, drug-associated cues, or
priming dose of nicotine? Will iptakalim have an impact on nicotine withdrawal or its
associated cognitive deficits? Does the action of iptakalim at ATP-sensitive potassium
channels contribute in a unique manner to its potential utility as a smoking cessation aid?
Although the present research eliminated inhibition of DAT or SERT function as a potential
mechanism, what other central nervous system effects of iptakalim contribute to its potential
efficacy and are these localized to particular brain regions? Addressing these questions, and
others, in future research will no doubt provide insight into iptakalim as a potential
medication for aiding in smoking cessation, as well as suggest potential new targets for
medication development.

Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

Charntikov et al.

Page 10

Acknowledgments
NIH-PA Author Manuscript

This work was in part supported by NIH research grant DA018114 and DA034389 to RAB and DA019447 to AEF,
as well as a grant from the Nebraska Department of Health and Human Services awarded to Ming Li. All MED-PC
programs used in the present article are available upon request.

References

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Balfour DJ. The neurobiology of tobacco dependence: a commentary. Respiration. 2002; 69(1):7–11.
[PubMed: 11844955]
Bardo MT, Valone JM, Bevins RA. Locomotion and conditioned place preference produced by acute
intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine
self-administration. Psychopharmacology (Berl). 1999; 143(1):39–46. [PubMed: 10227078]
Besheer J, Palmatier M, Metschke D, Bevins R. Nicotine as a signal for the presence or absence of
sucrose reward: a Pavlovian drug appetitive conditioning preparation in rats. Psychopharmacology
(Berl). 2004; 172(1):108–117. [PubMed: 14530902]
Bevins RA. The Reference-Dose Place Conditioning Procedure Yields a Graded Dose- Effect
Function. International Journal of Comparative Psychology. 2005; 18(2)
Bevins RA, Barrett ST, Polewan RJ, Pittenger ST, Swalve N, Charntikov S. Disentangling the nature
of the nicotine stimulus. Behavioural Processes. 2012; 90(1):28–33. [PubMed: 22119845]
Bevins RA, Palmatier MI. Extending the role of associative learning processes in nicotine addiction.
Behav Cogn Neurosci Rev. 2004; 3(3):143–158. [PubMed: 15653812]
Brioni JD, Kim DJ, Brodie MS, Decker MW, Arneric SP. ABT-418: discriminative stimulus properties
and effect on ventral tegmental cell activity. Psychopharmacology (Berl). 1995; 119(4):368–375.
[PubMed: 7480515]
Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. Cue dependency of
nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001; 70(4):515–530.
[PubMed: 11796151]
Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. Environmental stimuli
promote the acquisition of nicotine self-administration in rats. Psychopharmacology (Berl). 2002;
163(2):230–237. [PubMed: 12202970]
CDC. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses—United
States, 2000–2004. Morbidity and Mortality Weekly Report. 2008; 2010
Chandler CJ, Stolerman IP. Discriminative stimulus properties of the nicotinic agonist cytisine.
Psychopharmacology (Berl). 1997; 129(3):257–264. [PubMed: 9084064]
Charntikov S, Tracy ME, Zhao C, Li M, Bevins RA. Conditioned Response Evoked by Nicotine
Conditioned Stimulus Preferentially Induces c-Fos Expression in Medial Regions of CaudatePutamen. Neuropsychopharmacology. 2012; 37(4):876–884. [PubMed: 22048468]
Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L, et al. Operant responding for
conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary
reinforcing and reinforcement-enhancing effects of nicotine. Psychopharmacology (Berl). 2006;
189(1):27–36. [PubMed: 17019569]
Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L, et al. Self-administered and
noncontingent nicotine enhance reinforced operant responding in rats: impact of nicotine dose and
reinforcement schedule. Psychopharmacology (Berl). 2007; 190(3):353–362. [PubMed: 16847680]
Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. SSR591813, a novel selective
and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J
Pharmacol Exp Ther. 2003; 306(1):407–420. [PubMed: 12682217]
Corrigall W, Coen K. Nicotine maintains robust self-administration in rats on a limited-access
schedule. Psychopharmacology (Berl). 1989; 99(4):473–478. [PubMed: 2594913]
DeNoble VJ, Mele PC. Intravenous nicotine self-administration in rats: effects of mecamylamine,
hexamethonium and naloxone. Psychopharmacology (Berl). 2006; 184(3–4):266–272. [PubMed:
16088413]

Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

Charntikov et al.

Page 11

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J
Pharmacol. 2000; 393(1–3):295–314. [PubMed: 10771025]
Dion AM, Sanderson SC, Murrin LC, Bevins RA. Diminished conditioned responding to the nicotine
stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine
transporter. Pharmacol Biochem Behav. 2012; 100(3):419–424. [PubMed: 22005597]
Donny EC, Caggiula AR, Knopf S, Brown C. Nicotine self-administration in rats.
Psychopharmacology (Berl). 1995; 122(4):390–394. [PubMed: 8657839]
Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks Pa, Bardo MT. Nicotinic receptor-based
therapeutics and candidates for smoking cessation. Biochemical pharmacology. 2009; 78:732–43.
[PubMed: 19523455]
Farwell BJ, Ayres JJB. Stimulus-reinforcer and response-reinforcer relations in the control of
conditioned appetitive headpoking (‘goal tracking’) in rats. Learning and Motivation. 1979;
10:295–312.
Feltenstein MW, Ghee SM, See RE. Nicotine self-administration and reinstatement of nicotine-seeking
in male and female rats. Drug Alcohol Depend. 2012; 121(3):240–246. [PubMed: 21945235]
Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, et al. Evidence that nicotinic
alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J
Pharmacol Exp Ther. 2000; 294(3):1112–1119. [PubMed: 10945867]
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. 4-Methylmethcathinone
(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp
Ther. 2011; 339(2):530–536. [PubMed: 21810934]
Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals.
Pharmacol Biochem Behav. 1983; 19(6):989–992. [PubMed: 6657732]
Hu J, DeChon J, Yan KC, Liu Q, Hu G, Wu J. Iptakalim inhibits nicotinic acetylcholine receptormediated currents in dopamine neurons acutely dissociated from rat substantia nigra pars
compacta. Neurosci Lett. 2006; 403(1–2):57–62. [PubMed: 16730119]
Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH. Patterns of nicotinic receptor
antagonism: nicotine discrimination studies. J Pharmacol Exp Ther. 2011; 339(1):194–202.
[PubMed: 21730011]
Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on
addictive properties. Handb Exp Pharmacol. 2009; (192):335–367. [PubMed: 19184655]
LeSage MG, Shelley D, Ross JT, Carroll FI, Corrigall WA. Effects of the nicotinic receptor partial
agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.
Pharmacol Biochem Behav. 2009; 91(3):461–467. [PubMed: 18817808]
Liu Q, Li Z, Ding JH, Liu SY, Wu J, Hu G. Iptakalim inhibits nicotine-induced enhancement of
extracellular dopamine and glutamate levels in the nucleus accumbens of rats. Brain Res. 2006;
1085(1):138–143. [PubMed: 16647046]
Murray JE, Bevins RA. Behavioral and neuropharmacological characterization of nicotine as a
conditional stimulus. Eur J Pharmacol. 2007a; 561(1–3):91–104. [PubMed: 17343849]
Murray JE, Bevins RA. The conditional stimulus effects of nicotine vary as a function of training dose.
Behav Pharmacol. 2007b; 18(8):707–716. [PubMed: 17989508]
Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. Effect of a novel nicotinic receptor
antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration
and hyperactivity in rats. Psychopharmacology (Berl). 2006; 184(3–4):426–434. [PubMed:
16220336]
Palmatier MI, Liu X, Matteson GL, Donny EC, Caggiula AR, Sved AF. Conditioned reinforcement in
rats established with self-administered nicotine and enhanced by noncontingent nicotine.
Psychopharmacology (Berl). 2007; 195(2):235–243. [PubMed: 17676401]
Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. Acetylcholine receptors
containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;
391(6663):173–177. [PubMed: 9428762]
Polewan RJ, Savala SA, Bevins RA. Interoceptive conditioning with the nicotine stimulus: extinction
learning as a method for assessing stimulus similarity across doses. Behav Pharmacol: England.
2013; 24:45–54.

Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

Charntikov et al.

Page 12

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Pomerleau CS, Pomerleau OF. Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl).
1992; 108(4):460–465. [PubMed: 1410160]
Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine selfadministration in rats. Psychopharmacology (Berl). 2003; 169(1):1–9. [PubMed: 12811464]
Reichel CM, Linkugel JD, Bevins RA. Bupropion differentially impacts acquisition of
methamphetamine self-administration and sucrose-maintained behavior. Pharmacol Biochem
Behav. 2008; 89(3):463–472. [PubMed: 18329085]
Reichel CM, Murray JE, Barr JD, Bevins RA. Extinction with varenicline and nornicotine, but not
ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of
nicotine. Neuropharmacology. 2010; 58(8):1237–1245. [PubMed: 20302882]
Ross CA, Margolis RL, Reading SAJ, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron.
2006; 52:139–53. [PubMed: 17015232]
Schmidt E, Lecavalier D, Wu C, Yang K, Wu J. Dual Effects of Iptakalim on Nicotine-induced Rat
Behavioral Sensitization. Pharmacologia. 2012; 3(10):506–512.
Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence.
Expert Opin Emerg Drugs. 2006; 11(3):429–444. [PubMed: 16939383]
Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, et al. Ligands selective for alpha4beta2
but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus
in the rat. Psychopharmacology (Berl). 2007; 190(2):157–170. [PubMed: 17115136]
Smith JW, Stolerman IP. Recognising nicotine: the neurobiological basis of nicotine discrimination.
Handb Exp Pharmacol. 2009; (192):295–333. [PubMed: 19184654]
Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci. 1991; 12(12):
467–473. [PubMed: 1792691]
Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA. Mecamylamine, dihydro-betaerythroidine, and dextromethorphan block conditioned responding evoked by the conditional
stimulus effects of nicotine. Pharmacol Biochem Behav. 2009; 94(2):319–328. [PubMed:
19778551]
Sun T, Zhao C, Hu G, Li M. Iptakalim: a potential antipsychotic drug with novel mechanisms? Eur J
Pharmacol. 2010; 634(1–3):68–76. [PubMed: 20184878]
Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation
of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004; 306(5698):
1029–1032. [PubMed: 15528443]
Tobey KM, Walentiny DM, Wiley JL, Carroll FI, Damaj MI, Azar MR, et al. Effects of the specific
α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine rewardrelated behaviors in rats and mice. Psychopharmacology (Berl). 2012
Volf N, Hu G, Li M. Iptakalim Preferentially Decreases Nicotine-induced Hyperlocomotion in
Phencyclidine-sensitized Rats: A Potential Dual Action against Nicotine Addiction and Psychosis.
Clin Psychopharmacol Neurosci. 2012; 10(3):168–179. [PubMed: 23430396]
Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure
and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther.
2005a; 312(3):1326–1333. [PubMed: 15525792]
Wang H, Tang Y, Zhang YL. Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATPsensitive potassium channel opener targeting smaller arteries in hypertension. Cardiovasc Drug
Rev. 2005b; 23(4):293–316. [PubMed: 16614730]
Watkins SS, Epping-Jordan MP, Koob GF, Markou A. Blockade of nicotine self-administration with
nicotinic antagonists in rats. Pharmacol Biochem Behav. 1999; 62(4):743–751. [PubMed:
10208381]
Wee S, Wang Z, He R, Zhou J, Kozikowski AP, Woolverton WL. Role of the increased noradrenergic
neurotransmission in drug self-administration. Drug Alcohol Depend. 2006; 82(2):151– 157.
[PubMed: 16213110]
Wilkinson JL, Carroll FI, Bevins RA. An investigation of bupropion substitution for the interoceptive
stimulus effects of nicotine. J Psychopharmacol. 2010; 24(6):817–828. [PubMed: 19304864]

Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

Charntikov et al.

Page 13

NIH-PA Author Manuscript

Williams, BA. Reinforcement, choice, and response strength. In: Atkinson, RC.; Herrnstein, RJ.,
editors. Stevens’ handbook of experimental psychology. 2. Vol. 1. Wiley; New York: 1988. p.
167-244.Perception and motivation; Vol. 2: Learning and cognition
Wooters TE, Bevins RA, Bardo MT. Neuropharmacology of the interoceptive stimulus properties of
nicotine. Curr Drug Abuse Rev. 2009; 2(3):243–255. [PubMed: 20443771]
Zaniewska M, McCreary AC, Przegaliński E, Filip M. Evaluation of the role of nicotinic acetylcholine
receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Eur J Pharmacol. 2006; 540(1–3):96–106. [PubMed: 16730696]

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Neuropharmacology. Author manuscript; available in PMC 2014 December 01.

Charntikov et al.

Page 14

NIH-PA Author Manuscript

•

Iptakalim blocks responding evoked by the stimulus effects of nicotine

•

IV nicotine self-administration is blunted by pretreatment with iptakalim

•

Motor impairment cannot account for these effects

•

Iptakalim’s behavioral effects not due to SERT and DAT inhibition
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Figure 1.

Data representing discriminated goal-tracking tests. Upper panels show mean (±SEM)
dipper entries during iptakalim/nicotine interaction tests (A) and iptakalim alone tests (C).
Lower panels show mean (±SEM) number of chamber crosses during iptakalim/nicotine
interaction tests (B) and iptakalim alone tests (D). Dashed line represents saline control (0
mg/kg iptakalim + saline) activity baseline with dot lines delineating the SEM
boundaries. aSignificantly different from *, and † significantly different from b (p<0.05).
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Figure 2.
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Panel A shows mean (±SEM) lever presses during nicotine self-administration phase
(*significantly different from inactive lever; inset graph shows total infusions earned during
the session). Panel B shows mean (±SEM) lever presses during iptakalim dose-response
tests (*significantly different from 0 mg/kg active lever responding). Panel C shows mean
(±SEM) chamber crosses during the iptakalim dose-response tests (*significantly different
from 0 mg/kg; p<0.05).
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Figure 3.

Normalized [3H]DA uptake (A) and normalized [3H]5HTP uptake (B) following cocaine or
iptakalim treatment.
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